Cryoport, Inc.
NASDAQCYRX heads into Thursday's Q1 print with the stock up 60% over the past month and analysts chasing the move — the earnings call is now the first moment the market gets to decide whether the fundamentals deserve the re-rating. The analyst community has shifted into a clear gear. Craig-Hallum raised its target to $20 yesterday, the most bullish call on the Street and the freshest…
Snapshot as of 22 Jun 2026
CYRX heads into Thursday's Q1 print with the stock up 60% over the past month and analysts chasing the move — the earnings call is now the first moment the market gets to decide whether the fundamentals deserve the…
CYRX arrives at Thursday's Q1 earnings call with short sellers decisively pulling back, analysts raising targets, and the stock up 52% over the past month — making this week's print the first genuine test of whether…
Cryoport, Inc. heads into next month's Q2 earnings print with a split story: a sharp post-results re-rating that lifted the stock more than 25% in a month, a fresh analyst target raise from Keybanc this morning, and a…
CYRX reports Q1 2026 results tomorrow with the options market signalling unusually strong bullish conviction — the kind rarely seen in a small-cap life sciences name. The clearest positioning signal is the put/call…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CYRX — free to start on ORTEX.
Sign up for free →Open CYRX on ORTEX